ArticleBMJ open quality2019
Improving medication optimisation in left ventricular systolic dysfunction after acute myocardial infarction.
Article in BMJ open quality, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- From local change to scholarly contribution: lessons from a scoping review of the gaps and pitfalls of QI reports.BMJ open quality · 2026Article
- How will independent prescribing affect wellbeing and career progression for the pharmacists of tomorrow?Future healthcare journal · 2024Article
- Implementation and evaluation of pharmacist-led heart failure diagnostic and guideline directed medication therapies clinic.International journal of clinical pharmacy · 2024Article
- A qualitative study exploring the challenges and enablers of pharmacists with a recent background in community pharmacy transitioning into primary care.International journal of clinical pharmacy · 2024Article
- Developing a post-myocardial infarction medicines optimisation clinic: core competencies for upskilling pharmacists and initial patient feedback.BMJ open quality · 2023Review
- The Development of an Enhanced Palliative Care Pharmacy Service during the Initial COVID-19 Surge.Pharmacy (Basel, Switzerland) · 2021Article
- Advanced pharmacist practice: where is the United Kingdom in pursuit of this 'Brave New World'?International journal of clinical pharmacy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glasgow city has the highest cardiovascular disease (CVD) mortality rate in the UK. Patients with left ventricular systolic dysfunction after acute myocardial infarction represent a 'high-risk' cohort for adverse CVD outcomes. The optimisation of secondary prevention medication in this group is often suboptimal. Our aim was to improve the use and target dosing of ACE inhibitors (ACEI), angiotensin II receptor blockers (ARBs) and beta-blockers in such patients, through pharmacist-led clinics and cardiology multidisciplinary team collaboration. Retrospective audits characterised baseline care. Prospective pharmacist-led clinics were piloted and rolled out across seven hospitals and primary care localities over four Plan-Do-Study-Act cycles. 'Hub' and 'spoke' clinics utilised independent prescribing pharmacists with different levels of cardiology experience. Pharmacists were trained through a bespoke training programme-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.